BioMap Recognized as One of China's Top 50 Most Investable Healthcare Companies in 2024, Pioneering a New Paradigm in Life Science Innovation

May 19, 2025 09:53 CST Updated 09:53

BioMap

Developer of Innovative Drug R&D Platform

On May 15, 2025, the "2024 China Healthcare Industry Investment and Financing Honor Roll" jointly initiated by CHC Medical Consulting and CITIC Securities was officially released. BioMap successfully made it to the "Top 50 Most Investable Healthcare Companies of the Year" list due to its technological innovation capabilities, strategic planning, and industry practice achievements, demonstrating BioMap's comprehensive development potential in the healthcare field.

The list is based on five core dimensions: technological innovation, capital operation, commercialization process, social responsibility, and industrial collaboration. Through multiple rounds of review and data verification, it systematically evaluates the value creation capabilities of healthcare companies. The selection scope covers key areas such as pharmaceutical R&D, high-end medical devices, digital healthcare, and medical services, with a particular focus on enterprises' role in driving industrial upgrading and their ability to respond to clinical needs. This year’s evaluation added three new assessment criteria: breakthroughs in core technologies, global market expansion, and inclusive healthcare practices, emphasizing actual contributions to the construction of public health systems while focusing on business value growth.

As a representative enterprise in the life sciences field, BioMap has demonstrated outstanding advantages in technology transformation efficiency, industrial chain integration capabilities, and responsiveness to clinical needs. Against the backdrop of the implementation of the "Healthy China" strategy and medical technology innovation, this list not only recognizes outstanding enterprises but also provides a reference direction for industrial development. With the continuous strengthening of policy support, China's healthcare industry will achieve further development through technological innovation, model exploration, and international cooperation. Since its establishment, the "China Healthcare Industry Investment and Financing Honor Roll" has continuously tracked the development trends of the healthcare industry, selecting industry benchmark enterprises through a scientific evaluation system, and has now become an important reference for measuring the comprehensive strength of enterprises.

About BioMap

BioMap is a pioneer in global life sciences foundational large models. By leveraging a cross-modal biological language large model with 210 billion parameters, it decodes the underlying principles of genomes, proteins, cells, and biological systems, while consuming less data and cost to build high-quality AI task models for life sciences. Currently, BioMap has achieved State-of-the-Art (SOTA) performance in over 200 task models across drug discovery, biomanufacturing, healthcare, and other fields, serving more than 500 users globally. Its signed orders have a potential value of nearly $2 billion, enabling users to achieve numerous breakthroughs in AI-driven protein design, AI-based target discovery, and AI enzyme design. The company was co-founded by Robin Li, the founder of Baidu, and Wei Liu, former CEO of Baidu Ventures, with a core team comprising industry executives such as the former Global Vice President of Novo Nordisk and the former Global Vice President of SAP. R&D centers have been established in Silicon Valley, Beijing, Suzhou, and Hong Kong, and the company has secured over $200 million in venture capital.